NASDAQ: NLSP - NLS Pharmaceutics AG

Lønnsomhet i seks måneder: -72.24%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan NLS Pharmaceutics AG

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet NLS Pharmaceutics AG

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.

flere detaljer
The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2021-01-29
ISIN CH0523961370
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://nlspharma.com
Цена ао 1.53
Prisendring per dag: 0% (1.58)
Prisendring per uke: -7.06% (1.7)
Prisendring per måned: -31.3% (2.3)
Prisendring over 3 måneder: -15.05% (1.86)
Prisendring over seks måneder: -72.24% (5.692)
Prisendring per år: +485.62% (0.2698)
Prisendring over 3 år: +15.33% (1.37)
Prisendring over 5 år: 0% (1.58)
Prisendring over 10 år: 0% (1.58)
Prisendring siden begynnelsen av året: -20.2% (1.98)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV -77.55 0
P/E 0 0
EV/EBITDA -58.14 0
Total: 0.5

Effektivitet

Navn Betydning Karakter
ROA, % -659.14 0
ROE, % 137.79 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.1385 10
Total: 9.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 174.32 10
Lønnsomhet EPS, % -36.1 0
Total: 6
Flere detaljer

Institusjoner Volum Dele, %
BVF Inc. 5747126 17.72
Wells Fargo & Company 56549 0.17
Geode Capital Management, LLC 14362 0.04
Renaissance Technologies, LLC 12677 0.04
Bank of America Corporation 90 0



Veileder Stillingstittel Betaling Fødselsår
Mr. Alexander Zwyer M.B.A. CEO & Director 917k 1969 (56 år)
Dr. George Apostol M.D. Chief Medical Officer and Global Head of Research & Development 390k 1973 (52 år)
Dr. Eric Konofal M.D., Ph.D. Co-Founder & Chief Scientific Officer 179k 1967 (58 år)
Ms. Elena Thyen-Pighin CFO, Principal Accounting & Financial Officer and Head of Finance & Human Resources 61k 1972 (53 år)

Adresse: Switzerland, Zurich, The Circle 6 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://nlspharma.com